Novolizer (Formoterol Fumarate Dihydrate)

Formoterol fumarate dihydrate, the active ingredient in Novolizer, is a long‑acting β2‑adrenergic agonist (LABA) presented as a dry‑powder inhaler for inhalation use. It provides maintenance bronchodilation for asthma and chronic obstructive pulmonary disease (COPD) in adult patients.

GNH USA supplies Novolizer as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory‑approved batches to meet global demand. These supplies are distributed across Europe, Asia, Africa and the Americas, ensuring reliable access for respiratory care providers.

Formoterol, a long‑acting β2‑adrenergic agonist, is used in the management of chronic obstructive airway diseases.

Asthma: provides sustained bronchodilation to improve symptom control and reduce the need for rescue medication. COPD: enhances lung function and decreases the frequency of exacerbations in maintenance therapy. Exercise‑induced bronchoconstriction: prevents airway narrowing during physical activity when used as part of a regular regimen.

Formoterol may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Tremor: mild muscle shaking, often transient. - Headache: mild to moderate intensity. - Throat irritation: discomfort or dryness in the throat. - Cough: occasional irritation after inhalation. - Palpitations: awareness of heartbeat.

Serious or Rare Side Effects: - Paradoxical bronchospasm: sudden worsening of breathing. - Severe arrhythmias: irregular heart rhythm requiring medical attention. - Hypokalemia: low blood potassium levels. - Anaphylactic reaction: life‑threatening allergic response.

When prescribing Formoterol, clinicians should consider several safety precautions to minimize risk.

- Cardiovascular assessment: evaluate patients with heart disease before initiating therapy. - Monitor potassium: check serum potassium in patients on diuretics or with renal impairment. - Use with inhaled corticosteroid: combine with an anti‑inflammatory agent to reduce risk of asthma‑related death. - Avoid abrupt discontinuation: taper if long‑term use to prevent loss of bronchodilation. - Pregnancy and lactation: prescribe only if benefits outweigh potential risks. - Store at room temperature below 25°C: keep in original packaging, protect from moisture.

Formoterol can interact with other medicines, affecting its efficacy or safety.

Major Interactions (Avoid): - Non‑selective β‑blockers: block bronchodilator effect and may precipitate bronchospasm. - Diuretics (especially thiazides): increase risk of hypokalemia, enhancing cardiac effects. - Other LABAs: concurrent use may cause excessive β2 stimulation.

Moderate Interactions (Monitor Closely): - Theophylline: may increase risk of tachyarrhythmias. - Anticholinergic bronchodilators: additive bronchodilation may require dose adjustment. - Digoxin: monitor for increased serum levels due to electrolyte shifts. - ACE inhibitors: watch for cough or angioedema when combined.